The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now

Pharmaceutical dividend trade-offs are stark: Pfizer yields about 6.6% but carries a payout ratio north of 100% and faces near-term patent cliffs (Ibrance, Eliquis, Vyndaqel in 2027–28) plus a failed GLP‑1 candidate, while Eli Lilly is the top growth story (Mounjaro sales +109% and Zepbound +185% YoY in Q3 2025) but offers only a ~0.6% yield with a ~30% payout ratio. Merck presents a middle ground for income-focused investors — roughly a 3.4% yield with a ~45% payout ratio, more durable patent protections for Keytruda internationally and a secondary-protected version into the late 2030s, and strategic pipeline bolstering via a ~$9 billion Cidara acquisition — making it a more balanced option between yield and dividend sustainability.

Analysis

The article frames a clear trade-off across three pharma names: Pfizer offers a high 6.6% yield but a payout ratio north of 100%, Eli Lilly generates strong growth (Mounjaro sales +109% and Zepbound +185% year-over-year in Q3 2025) with a low yield near 0.6% and roughly a 30% payout ratio, and Merck represents a middle ground with ~3.4% yield and a ~45% payout ratio. Eli Lilly’s GLP-1 momentum explains its premium growth profile but not income appeal, while Pfizer’s high yield is undermined by its unusually high payout and strategic setbacks, including a failed GLP-1 candidate and a pivot toward acquisitions and partnerships. Pfizer also faces material patent expirations—Ibrance, Eliquis, and Vyndaqel between 2027 and 2028—that amplify dividend risk if cash generation weakens. Merck’s profile combines a more sustainable payout with patent protections for Keytruda extending internationally into the early 2030s and a later-version protection into the late 2030s, plus a roughly $9 billion acquisition of Cidara to bolster its pipeline, making it a more balanced income candidate though not free of risk.

Key Decisions for Investors

• Consider using Merck as the core income-weighted pharma holding given its ~3.4% yield and ~45% payout ratio, sizing exposure to the portion of your portfolio that requires dependable dividends
• Avoid heavy reliance on Pfizer for living-income needs because the payout ratio above 100% and patent cliffs for Ibrance, Eliquis and Vyndaqel in 2027–28 create near-term sustainability risk; if holding, use a smaller or hedged position
• Maintain growth exposure to Eli Lilly for GLP-1 upside (Mounjaro +109% and Zepbound +185% YoY in Q3 2025) but accept it as a low-income, growth-oriented position given the ~0.6% yield
• Actively monitor Merck’s integration of the ~$9 billion Cidara deal, Keytruda patent timelines, and any shifts in payout ratio or cash flow metrics and be prepared to reallocate if dividend coverage deteriorates